Share This Page
PYZCHIVA Drug Profile
✉ Email this page to a colleague
Summary for Tradename: PYZCHIVA
| High Confidence Patents: | 0 |
| Applicants: | 1 |
| BLAs: | 2 |
Pharmacology for PYZCHIVA
| Mechanism of Action | Interleukin-12 Antagonists Interleukin-23 Antagonists |
| Established Pharmacologic Class | Interleukin-12 Antagonist Interleukin-23 Antagonist |
Note on Biologic Patents
Matching patents to biologic drugs is far more complicated than for small-molecule drugs.
DrugPatentWatch employs three methods to identify biologic patents:
- Brand-side disclosures in response to biosimilar applications
- DrugPatentWatch analysis and company disclosures
- Patents from broad patent text search
These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.
These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.
1) High Certainty: US Patents for PYZCHIVA Derived from Brand-Side Litigation
No patents found based on brand-side litigation
2) High Certainty: US Patents for PYZCHIVA Derived from DrugPatentWatch Analysis and Company Disclosures
No patents found based on company disclosures
3) Low Certainty: US Patents for PYZCHIVA Derived from Patent Text Search
No patents found based on company disclosures
PYZCHIVA Market Dynamics and Financial Trajectory: Ustekinumab Biosimilar Analysis
Pyzchiva is Sandoz’s ustekinumab biosimilar to Stelara, marketed as ustekinumab-ttwe in the United States. Its commercial outlook depends on rapid uptake in psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, but pricing pressure will intensify as multiple ustekinumab biosimilars enter the market. Sandoz does not report Pyzchiva revenue separately, so the product’s financial trajectory must be assessed through launch timing, market access, biosimilar competition, and Sandoz’s broader biosimilars performance.
What is Pyzchiva and which drug does it compete with?
Pyzchiva is a monoclonal antibody biosimilar referencing Stelara, Janssen’s ustekinumab product. Ustekinumab inhibits interleukin-12 and interleukin-23 signaling and is used across immune-mediated inflammatory diseases.
| Attribute | Pyzchiva |
|---|---|
| Active ingredient | Ustekinumab-ttwe |
| Reference product | Stelara |
| Developer | Sandoz |
| Drug class | Monoclonal antibody biosimilar |
| FDA pathway | 351(k) biosimilar pathway |
| U.S. indications | Plaque psoriasis, psoriatic arthritis, Crohn’s disease, ulcerative colitis |
| Dosage forms | Intravenous induction formulation and subcutaneous maintenance formulations |
| Interchangeability | FDA interchangeable designation reported in 2025 |
| Principal markets | United States, European Union and other regulated markets |
The product’s commercial value is tied to Stelara’s large installed patient base and high biologic treatment costs. Stelara generated approximately $10.9 billion in global sales in 2023, making ustekinumab one of the largest biosimilar opportunities in immunology (Johnson & Johnson, 2024).
When did Pyzchiva receive FDA approval and launch in the United States?
The FDA approved Pyzchiva in 2024 for the same principal inflammatory diseases covered by Stelara’s reference approval. Sandoz entered the U.S. market after a settlement with Janssen governing the timing of commercial launch.
Sandoz stated that Pyzchiva would launch in the United States in 2025. The product’s U.S. commercial entry followed the settlement framework that allowed selected ustekinumab biosimilars to enter before the full expiration of all asserted Stelara-related patent rights.
The FDA’s biosimilar approval does not itself determine launch timing. Commercial entry depends on patent settlements, supply readiness, payer contracting, product labeling, and the availability of the relevant induction and maintenance presentations.
What is the FDA regulatory status of Pyzchiva?
Pyzchiva has FDA approval as a biosimilar to Stelara. Its label covers:
- Moderate-to-severe plaque psoriasis in adults and eligible pediatric patients.
- Active psoriatic arthritis.
- Moderately to severely active Crohn’s disease.
- Moderately to severely active ulcerative colitis.
The FDA’s interchangeability designation is commercially important because it can support pharmacy-level substitution under applicable state law. Interchangeability does not create automatic substitution in every state, and payer policies remain a separate commercial variable.
What is the Orange Book or Purple Book status of Pyzchiva?
Pyzchiva is listed in the FDA Purple Book rather than the Orange Book. The Orange Book primarily covers approved small-molecule drugs and certain related products, while the Purple Book contains licensed biological products, biosimilars, and interchangeable biosimilars.
The Purple Book establishes the regulatory relationship between Pyzchiva and Stelara. It does not provide a complete substitute for private patent diligence. Biosimilar patent disputes can involve patents covering the reference product, formulations, manufacturing processes, dosing regimens, and other aspects of the biologic product.
What patents protect Pyzchiva and when does ustekinumab lose exclusivity?
Pyzchiva is not protected by the same product patent estate as Stelara. Its development relies on biosimilarity to the reference product, while its commercial risk is driven by Stelara-related patents, patent settlements, and any Sandoz-specific intellectual property covering manufacturing or formulation.
The central exclusivity event was the expiration of Stelara’s key composition-of-matter protection. Later patent disputes focused on secondary patents and commercial launch timing. These patents can extend litigation risk even after the principal molecule patent expires.
Which patents and legal rights matter commercially?
The relevant rights fall into four groups:
- Stelara composition and antibody patents.
- Formulation and stability patents.
- Dosing, treatment, and disease-specific method-of-use patents.
- Manufacturing and cell-line process patents.
For Pyzchiva, the highest-value legal issue is not whether Sandoz can obtain FDA approval. It is whether Sandoz can sell each presentation and indication without infringing enforceable secondary patents.
Janssen has used patent litigation and settlements to manage the timing of ustekinumab biosimilar launches. Settlement terms can permit entry on an agreed date without resolving every patent claim through a final judgment. The commercial date is therefore more important than the nominal expiration date of an individual patent.
What patent litigation and settlement agreements affect Pyzchiva?
Sandoz reached a settlement with Janssen relating to ustekinumab biosimilar commercialization in the United States. The agreement permitted a defined U.S. launch timetable. Publicly available settlement disclosures generally identify the permitted entry date and legal parties, while detailed economic terms may remain confidential.
The settlement reduced the risk of an injunction preventing launch, but it did not eliminate commercial risk. Sandoz still faces:
- Possible patent enforcement involving later-issued or non-settled rights.
- Product-specific manufacturing claims.
- Competition from other ustekinumab biosimilars entering under separate settlements.
- Pricing pressure after multiple products reach the market.
- State substitution and payer restrictions affecting interchangeable products.
No public information supports treating Pyzchiva as insulated from all future patent litigation. Its practical risk is lower than that of a first entrant operating without a settlement, but the risk is not zero.
How many biosimilars compete with Pyzchiva?
Pyzchiva is entering a crowded ustekinumab biosimilar market. Key competitors include Amgen’s Wezlana and Teva/Alvotech’s Selarsdi in the United States, along with multiple products approved or commercialized in Europe.
| Product | Company | Reference product | U.S. status |
|---|---|---|---|
| Pyzchiva | Sandoz | Stelara | FDA-approved biosimilar; U.S. launch in 2025 |
| Wezlana | Amgen | Stelara | FDA-approved biosimilar and interchangeable product |
| Selarsdi | Teva/Alvotech | Stelara | FDA-approved biosimilar |
| Uzpruvo | STADA/Alvotech | Stelara | European biosimilar |
| Other regional products | Various manufacturers | Stelara | Market-specific approvals and launches |
The competitive structure is unfavorable for premium pricing. Stelara’s market is large, but the number of credible suppliers increases the probability of rapid discounts, restricted formulary access, and rebate competition.
How does Pyzchiva compare with Wezlana and Selarsdi?
Pyzchiva has three principal competitive variables:
- Launch timing.
- Interchangeability and substitution potential.
- Payer contracting and supply reliability.
Amgen has an established U.S. commercial infrastructure and deep payer relationships. Sandoz has extensive biosimilar experience and a broad global portfolio. Teva and Alvotech combine Teva’s U.S. commercial platform with Alvotech’s biosimilar development and manufacturing capabilities.
Pyzchiva’s competitive position will improve if Sandoz secures preferred formulary placement, maintains reliable supply of both intravenous and subcutaneous presentations, and uses interchangeability to support pharmacy and health-plan adoption.
What formulations are protected by the Stelara patent estate?
Stelara is sold in multiple dosage forms, and each presentation creates separate regulatory and commercial considerations.
Intravenous formulation
The intravenous product is used for induction in Crohn’s disease and ulcerative colitis. Manufacturing complexity, cold-chain requirements, hospital procurement, and infusion-center protocols can slow switching from Stelara.
Subcutaneous formulation
The subcutaneous presentation is used for maintenance therapy and is more exposed to payer-driven substitution. Patient support, device design, injection volume, packaging, and pharmacy distribution influence conversion rates.
Formulation patents can delay or complicate entry even when the active antibody is no longer protected by a primary patent. A biosimilar may receive approval for the reference product’s indications while still requiring careful launch planning around patent claims directed to specific presentations or uses.
What is the market size for Pyzchiva?
The addressable market is based on Stelara’s global sales, not on the entire immunology biologics market. Stelara produced roughly $10.9 billion in 2023 revenue, with the United States representing the largest commercial opportunity (Johnson & Johnson, 2024).
The main demand pools are:
- Dermatology, including plaque psoriasis.
- Rheumatology, including psoriatic arthritis.
- Gastroenterology, including Crohn’s disease and ulcerative colitis.
The gastrointestinal indications are particularly important because they use intravenous induction followed by subcutaneous maintenance therapy. This creates a broader product opportunity than a single-dose outpatient dermatology product.
Pyzchiva’s realized market share will depend on the proportion of Stelara patients who switch, the number of new patients placed on a biosimilar, and the discount required to win payer access.
What is the financial trajectory for Pyzchiva?
Sandoz does not disclose standalone Pyzchiva sales, gross margin, operating profit, or patient volume. The product is reported within broader Sandoz biosimilars results rather than as a separate public reporting unit.
The likely financial trajectory has four stages.
Stage 1: Pre-launch investment
Before launch, Sandoz incurred development, regulatory, manufacturing, legal, and commercial preparation costs. Biosimilar development requires substantial analytical characterization, clinical comparability work, regulatory filings, and manufacturing scale-up.
Stage 2: Launch-year revenue ramp
Revenue should rise rapidly after U.S. launch if Sandoz obtains broad payer access. Initial sales are likely to come from:
- New prescriptions where payers mandate lower-cost biologics.
- Patients switching from Stelara.
- Contracts with integrated delivery networks.
- European markets where biosimilar substitution and tendering are more advanced.
The U.S. launch is likely to create the largest incremental revenue opportunity, but the market may also produce the steepest discounting.
Stage 3: Multi-product price compression
As Wezlana, Selarsdi, Pyzchiva, and other ustekinumab biosimilars compete, net prices are likely to decline. Revenue growth may continue while gross margin falls if volume growth does not offset price erosion.
A first-wave biosimilar can preserve attractive economics if it secures preferred access before the market becomes saturated. A later entrant may still gain share through lower pricing, but margin quality is usually weaker.
Stage 4: Mature share and portfolio contribution
At maturity, Pyzchiva should be evaluated as part of Sandoz’s broader biosimilar portfolio. Its strategic value includes:
- Expanding Sandoz’s immunology franchise.
- Improving payer negotiating leverage.
- Increasing manufacturing utilization.
- Supporting cross-selling across specialty channels.
- Replacing revenue lost from older biosimilar products facing price erosion.
What generic and biosimilar launch risks exist for Pyzchiva?
Pyzchiva faces biosimilar-specific risks rather than conventional generic risks. The major risks are:
| Risk | Commercial effect |
|---|---|
| Multiple same-reference competitors | Faster net-price erosion |
| Payer exclusion | Lower prescription conversion |
| Limited substitution rules | Reduced value of interchangeability |
| Manufacturing interruption | Loss of payer confidence and contracts |
| Complex IV induction logistics | Slower gastroenterology uptake |
| Patent enforcement | Launch delay or added legal cost |
| Physician inertia | Lower switching from Stelara |
| Patient assistance disruption | Reduced adherence and conversion |
The product’s most important operational risk is supply continuity. Hospitals and specialty pharmacies may resist switching if the supplier cannot reliably provide both the induction and maintenance regimens.
Which companies are challenging Stelara’s market position?
The competitive challenge comes from biosimilar manufacturers rather than a single generic company. Amgen, Sandoz, Teva, and Alvotech are among the most relevant U.S. participants. European competition is broader because regulatory approval and tender markets have enabled earlier ustekinumab biosimilar commercialization.
Janssen also faces therapeutic competition from newer biologics and targeted therapies, including IL-23 inhibitors such as Tremfya, Skyrizi, and Ilumya. These products can reduce the pool of patients eligible for Stelara or its biosimilars, particularly in psoriasis and inflammatory bowel disease.
Pyzchiva therefore competes on two levels:
- Directly against other ustekinumab biosimilars.
- Indirectly against newer mechanisms with potentially stronger efficacy, convenience, or physician preference.
How strong is the Pyzchiva patent and commercial estate?
Pyzchiva’s direct patent estate is less important than its regulatory, manufacturing, and commercial platform. Biosimilar value depends on the ability to commercialize a product that is highly similar to Stelara after reference-product exclusivity barriers fall.
Sandoz’s strengths include:
- Experience launching biosimilars globally.
- Established regulatory capabilities.
- Existing specialty-pharmacy and payer relationships.
- A broad manufacturing network.
- The ability to bundle Pyzchiva with other biosimilar products.
Its weaknesses include exposure to price competition and the absence of product-level public financial disclosure. The commercial estate is strongest where Sandoz can obtain preferred payer status and maintain reliable supply across all major presentations.
What revenue exposure does Stelara have to biosimilar competition?
Stelara’s approximately $10.9 billion 2023 sales base creates substantial exposure for Janssen and a large opportunity for biosimilar manufacturers. The erosion curve will not be uniform across geographies or indications.
The United States is likely to experience:
- High launch discounts.
- Strong payer negotiation.
- Rapid competition after multiple approvals.
- Slower physician switching in complex gastrointestinal patients.
- Greater substitution potential for interchangeable products.
Europe is likely to experience more tendering and faster price compression in markets with established biosimilar adoption. The result is a trade-off: earlier access in some European markets, but lower net pricing.
What is the outlook for Pyzchiva through 2027?
Pyzchiva’s base-case outlook is positive for revenue growth but pressured for margins.
| Period | Expected market dynamic | Financial implication |
|---|---|---|
| 2024 | Regulatory approval and market preparation | High upfront investment |
| 2025 | U.S. launch and early payer contracting | Fast revenue ramp; launch discounts |
| 2026 | More competitors and broader switching | Volume growth with lower net price |
| 2027 | Mature multi-biosimilar market | Share stability becomes more important than launch timing |
The strongest scenario occurs if Sandoz wins preferred payer access, achieves broad use of the interchangeable label, and maintains supply leadership. The downside scenario is a fragmented market in which payers rotate among multiple products and force deep discounts.
Pyzchiva is more likely to become a meaningful portfolio contributor than a standalone blockbuster. Its commercial success will be measured by market share, contribution margin, contract retention, and manufacturing utilization rather than reported absolute revenue alone.
Key Takeaways
- Pyzchiva is Sandoz’s ustekinumab-ttwe biosimilar to Stelara.
- Stelara generated approximately $10.9 billion globally in 2023, creating a large biosimilar opportunity.
- FDA approval covers psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
- U.S. commercialization began in 2025 under a Janssen settlement framework.
- The principal competitors are Wezlana from Amgen and Selarsdi from Teva/Alvotech.
- Sandoz does not publicly report Pyzchiva-specific revenue or profit.
- Revenue should increase sharply after U.S. launch, while net pricing and margins will face pressure from multiple entrants.
- Interchangeability, payer access, supply reliability, and gastrointestinal induction logistics are the main commercial differentiators.
- The product’s direct patent position matters less than Stelara-related secondary patents, settlements, and manufacturing execution.
- Pyzchiva’s most likely role is a significant contributor to Sandoz’s biosimilars portfolio rather than a single-product blockbuster.
FAQs
Is Pyzchiva cheaper than Stelara?
Pyzchiva is expected to be priced below Stelara, but the effective net price depends on payer rebates, pharmacy contracts, distribution arrangements, and launch discounts. Public list prices do not capture the full commercial discount.
Can pharmacists automatically substitute Pyzchiva for Stelara?
Automatic substitution depends on the FDA interchangeability designation and the law of the applicable state or jurisdiction. The interchangeable label improves substitution potential but does not override state pharmacy rules or payer policies.
Does Pyzchiva treat ulcerative colitis and Crohn’s disease?
Yes. FDA approval covers both Crohn’s disease and ulcerative colitis, including intravenous induction and subcutaneous maintenance treatment.
Is Pyzchiva available outside the United States?
Sandoz has pursued ustekinumab biosimilar commercialization in multiple international markets. Availability, brand name, reimbursement, and launch timing vary by country.
Will Stelara biosimilars reduce Janssen’s revenue immediately?
Revenue erosion is likely to develop in stages. Payer contracting can produce rapid declines in selected accounts, while physician adoption and switching in chronic inflammatory disease may take longer. The timing depends on the number of approved competitors and their launch discounts.
References
-
European Medicines Agency. (2024). Uzpruvo: EPAR - Product information. https://www.ema.europa.eu/
-
U.S. Food and Drug Administration. (2024). Biosimilar product information: Pyzchiva (ustekinumab-ttwe). https://www.fda.gov/
-
U.S. Food and Drug Administration. (2025). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/
-
Johnson & Johnson. (2024). 2023 annual report. https://www.jnj.com/
-
Sandoz Group AG. (2024). Sandoz announces U.S. FDA approval of Pyzchiva, a biosimilar to Stelara. https://www.sandoz.com/
-
Amgen Inc. (2024). Amgen announces FDA approval of Wezlana, an interchangeable biosimilar to Stelara. https://www.amgen.com/
-
Teva Pharmaceutical Industries Ltd. (2025). FDA approval of Selarsdi, a biosimilar to Stelara. https://www.tevapharm.com/
More… ↓
